Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution

Anesthesiology

Volumn 113, Issue 5, 2010, Pages 1205-1219

  Bolliger, Daniel ^a   Görlinger, Klaus ^b   Tanaka, Kenichi A ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN ACETATE; FIBRIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FIBRINOGEN RECEPTOR; FRESH FROZEN PLASMA; INTEGRIN RECEPTOR; PROTEIN C; PROTEIN S; PROTEINASE INHIBITOR; PROTHROMBIN; RECOMBINANT ACTIVATED BLOOD CLOTTING FACTOR 7; THROMBIN; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CLINICAL TRIAL; CRYOPRECIPITATE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FIBRIN CLOT; FIBRIN POLYMERIZATION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; FLUID RESUSCITATION; HEMODILUTION; HUMAN; LOADING DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBOCYTE ACTIVATION; THROMBOELASTOGRAPHY; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT INDICATION; ANIMAL; BLOOD COAGULATION DISORDERS; HEMORRHAGE; POSTOPERATIVE HEMORRHAGE; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BLOOD COAGULATION DISORDERS; HEMODILUTION; HEMORRHAGE; HUMANS; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

EID: 78049340172     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181f22b5a     Document Type: Review

References (152)

1. American Society of Anesthesiologists Task Force on Peri-operative Blood Transfusion and Adjuvant Therapies: Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on Perioper-ative Blood Transfusion and Adjuvant Therapies. ANESTHE-SIOLOGY 2006; 105:198-208
2. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarza-bal LA, Schreiber MA, Gonzalez EA, Pomper GJ, Perkins JG, Spinella PC, Williams KL, Park MS: Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447-58
3. Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR: Blood transfusion rates in the care of acute trauma. Transfusion 2004; 44:809-13
4. Vaslef SN, Knudsen NW, Neligan PJ, Sebastian MW: Massive transfusion exceeding 50 units of blood products in trauma patients. J Trauma 2002; 53:291-5
5. Hardy JF, de Moerloose P, Samama CM: The coagulopathy of massive transfusion. Vox Sang 2005; 89:123-7
6. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, Hoyt DB, Bouillon B: The coagulopathy of trauma: A review of mechanisms. J Trauma 2008; 65:748-54
7. Ide M, Bolliger D, Taketomi T, Tanaka KA: Lessons from the aprotinin saga: Current perspective on antifibrino-lytic therapy in cardiac surgery. J Anesth 2010; 24:96-106
8. Levy JH: Massive transfusion coagulopathy. Semin Hema-tol 2006; 43:S59-63
9. Brohi K, Singh J, Heron M, Coats T: Acute traumatic coagulopathy. J Trauma 2003; 54:1127-30
10. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA: Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: Implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010; 104:318-25
11. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA: Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: An in vitro model. Br J Anaesth 2009; 102:793-9
12. Grant PJ: Hormonal regulation of the acute haemostatic response to stress. Blood Coagul Fibrinolysis 1990; 1:299-306
13. Harker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ: Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56:824-34
14. Weinstein M, Ware JA, Troll J, Salzman E: Changes in von Willebrand factor during cardiac surgery: Effect of des-mopressin acetate. Blood 1988; 71:1648-55
15. Reed RL, 2nd, Ciavarella D, Heimbach DM, Baron L, Pavlin E, Counts RB, Carrico CJ: Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Ann Surg 1986; 203:40-8
16. Hiippala ST, Myllylä GJ, Vahtera EM: Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360-5
17. Dirkmann D, Hanke AA, Görlinger K, Peters J: Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106:1627-32
18. Martini WZ: Coagulopathy by hypothermia and acidosis: Mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009; 67:202-8
19. Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M: The effect of temperature and pH on the activity of factor VIIa: Implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886-91
20. Jesty J, Beltrami E: Positive feedbacks of coagulation: Their role in threshold regulation. Arterioscler Thromb Vasc Biol 2005; 25:2463-9
21. Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA: Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg 2008; 106:713-8
22. Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA: Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb Hae-most 2010; 103:1233-8
23. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, Katabami K: Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res 2009; 124:608-13
24. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M: Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63:877-84
25. Ichinose A, Tamaki T, Aoki N: Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett 1983; 153:369-71
26. Mosesson MW, Siebenlist KR, Hernandez I, Lee KN, Christiansen VJ, McKee PA: Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: A new role for plasma factor XIII in fibrino-lysis regulation. J Thromb Haemost 2008; 6:1565-70
27. Wettstein P, Haeberli A, Stutz M, Rohner M, Corbetta C, Gabi K, Schnider T, Korte W: Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99:1564-9
28. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L: Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78:386-91
29. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN: Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
30. Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA: Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Haemophilia 2010; 16:510-7
31. Booth NA, Reith A, Bennett B: A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy. Thromb Haemost 1988; 59:77-9
32. Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, Mascolo G, Grandone E, Di Minno G: PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: Relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18:562-7
33. Emeis JJ: Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann N Y Acad Sci 1992; 667: 249-58
34. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS: Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792-7
35. Schöchl H, Frietsch T, Pavelka M, Jámbor C: Hyperfibrin-olysis after major trauma: Differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67:125-31
36. Butenas S, Dee JD, Mann KG: The function of factor XI in tissue factor-initiated thrombin generation. J Thromb Haemost 2003; 1:2103-11
37. Hoffman M, Monroe DM 3rd: A cell-based model of he-mostasis. Thromb Haemost 2001; 85:958-65
38. Tanaka KA, Key NS, Levy JH: Blood coagulation: Hemo-stasis and thrombin regulation. Anesth Analg 2009; 108: 1433-46
39. Mann KG, Butenas S, Brummel K: The dynamics of throm-bin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25
40. Wolberg AS, Campbell RA: Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci 2008; 38:15-23
41. Lane DA, Philippou H, Huntington JA: Directing throm-bin. Blood 2005; 106:2605-12
42. Baugh RJ, Broze GJ Jr., Krishnaswamy S: Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273:4378-86
43. Hackeng TM, Seré KM, Tans G, Rosing J: Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci \USA 2006; 103:3106-11
44. Lisman T, Bakhtiari K, Pereboom IT, Hendriks HG, Mei-jers JC, Porte RJ: Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52:355-61
45. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazza-niga M, Primignani M, Mannuccio Mannucci P: Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553-8
46. Fenger-Eriksen C, Tønnesen E, Ingerslev J, Sørensen B: Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost 2009; 7:1099-105
47. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM: Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106:4176-83
48. Hathcock JJ, Nemerson Y: Platelet deposition inhibits tissue factor activity: In vitro clots are impermeable to factor Xa. Blood 2004; 104:123-7
49. Gando S: Acute coagulopathy of trauma shock and coagu-lopathy of trauma: A rebuttal. You are now going down the wrong path. J Trauma 2009; 67:381-3
50. Martini WZ, Pusateri AE, Uscilowicz JM, Delgado AV, Holcomb JB: Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma 2005; 58:1002-9
51. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost D, PPH Study Group: The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266-73
52. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL: The origins of age-related proinflammatory state. Blood 2005; 105:2294-9
53. Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM: Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55:841-7
54. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Col-ler BS, Jordan RE: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88:907-14
55. Weisel JW: Fibrin assembly. Lateral aggregation and the role of the two pairs of fibrinopeptides. Biophys J 1986; 50:1079-93
56. Korte WC, Szadkowski C, Gähler A, Gabi K, Kownacki E, Eder M, Degiacomi P, Zoller N, Devay J, Lange J, Schnider T: Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. ANESTHESIOLOGY 2009; 110:239-45
57. Wolberg AS, Monroe DM, Roberts HR, Hoffman M: Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased throm-botic risk. Blood 2003; 101:3008-13
58. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW: Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy. Arterio-scler Thromb Vasc Biol 2000; 20:1354-61
59. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M: High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131:645-55
60. Dale GL, Remenyi G, Friese P: Quantitation of micropar-ticles released from coated-platelets. J Thromb Haemost 2005; 3:2081-8
61. Sniecinski RM, Chen EP, Tanaka KA: Reduced levels of fibrin (antithrombin I) and antithrombin III underlie co-agulopathy following complex cardiac surgery. Blood Coagul Fibrinolysis 2008; 19:178-9
62. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF: Acute coagulopathy of trauma: Hypoperfusion induces systemic anticoagulation and hy-perfibrinolysis. J Trauma 2008; 64:1211-7
63. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM, British Committee for Standards in Haematology, Blood Transfusion Task Force: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11-28
64. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R: Management of bleeding following major trauma: A European guideline. Crit Care 2007; 11:R17
65. Mason DY, Ingram GI: Management of the hereditary coagulation disorders. Semin Hematol 1971; 8:158-88
66. Cross-sectional guidelines for therapy with blood components and plasma derivatives: Chapter 7 Procoagulators. Transfus Med Hemother 2009; 36:419-36
67. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR: Management of bleeding following major trauma: An updated European guideline. Crit Care 2010; 14:R52
68. Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, Tanaka KA: Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: A pilot study. Br J Anaesth 2009; 102:785-92
69. Bolliger D, Gonsahn M, Levy JH, Williams WH, Tanaka KA: Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery? Transfusion 2009; 49:2006-7
70. Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P, Saggau W: Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93:1101-7
71. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A: Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009; 102:137-44
72. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tønnesen E, Ingerslev J, Sørensen B: Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: A randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7:795-802
73. Hiippala ST: Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagul Fibrinolysis 1995; 6:743-6
74. Gerlach R, Tölle F, Raabe A, Zimmermann M, Siegemund A, Seifert V: Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: Implications of a prospective study. Stroke 2002; 33:1618-23
75. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA: Competition between plasminogen and tissue plasmino-gen activator for cellular binding sites. Blood 1993; 82: 2433-41
76. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procar-boxypeptidase B, couples the coagulation and fibrino-lytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271:16603-8
77. Sakata Y, Aoki N: Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65:290-7
78. Sakharov DV, Nagelkerke JF, Rijken DC: Rearrangements of the fibrin network and spatial distribution of fibrino-lytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271:2133-8
79. Taketomi T, Szlam F, Levy JH, Tanaka KA: Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombi-nant activated factor VII. Blood Coagul Fibrinolysis 2008; 19:106-8
80. Mao SS, Holahan MA, Bailey C, Wu G, Colussi D, Carroll SS, Cook JJ: Demonstration of enhanced endogenous fi-brinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul Fibrinolysis 2005; 16: 407-15
81. Martini WZ, Holcomb JB: Acidosis and coagulopathy: The differential effects on fibrinogen synthesis and breakdown in pigs. Ann Surg 2007; 246:831-5
82. Martini WZ: The effects of hypothermia on fibrinogen metabolism and coagulation function in swine. Metabolism 2007; 56:214-21
83. Yuan S, Ferrell C, Chandler WL: Comparing the pro-thrombin time INR versus the APTT to evaluate the co-agulopathy of acute trauma. Thromb Res 2007; 120:29-37
84. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C: Diagnosis of early coagulation abnormalities in trauma patients by rotation throm-belastography. J Thromb Haemost 2007; 5:289-95
85. Mann KG: Thrombin formation. Chest 2003; 124:4S-10S
86. Hartert H: Blutgerinnungsstudien mit der Thromboelas-tographie, einem neuen Untersuchungsverfahren. Klin Wochenschrift 1948; 26:557-83
87. Hvas AM, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B: Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5:2408-14
88. Jámbor C, Reul V, Schnider TW, Degiacomi P, Metzner H, Korte WC: In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrino-lytic effects in whole blood. Anesth Analg 2009; 109: 1023-8
89. Spiezia L, Radu C, Marchioro P, Bertini D, Rossetto V, Castelli M, Pagnan A, Sørensen B, Simioni P: Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thromb Haemost 2008; 100:1106-10
90. Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C: Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM(R))-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14:R55
91. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA: The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009; 108:751-8
92. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Inner-hofer P: Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: The role of fibrinogen administration. Anesth Analg 2007; 105:905-17
93. Can MM, Tanbog?a IH, Türkyilmaz E, Karabay CY, Akgun T, Koca F, Tokgoz HC, Keles N, Ozkan A, Bezgin T, Ozveren O, Sonmez K, Sag?lam M, Ozdemir N, Kaymaz C: The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res 2010; 125:e132-7
94. Gutierrez G, Reines HD, Wulf-Gutierrez ME: Clinical review: Hemorrhagic shock. Crit Care 2004; 8:373-81
95. Kozek-Langenecker SA: Effects of hydroxyethyl starch solutions on hemostasis. ANESTHESIOLOGY 2005; 103: 654-60
96. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Innerhofer P: Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo. Br J Anaesth 2008; 100:307-14
97. Fries D, Innerhofer P, Klingler A, Berresheim U, Mitter-mayr M, Calatzis A, Schobersberger W: The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: An in vitro study using thrombelastograph coagulation analysis (ROTEG). Anesth Analg 2002; 94:1280-7
98. de Jonge E, Levi M, Berends F, van der Ende AE, ten Cate JW, Stoutenbeek CP: Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 1998; 79:286-90
99. Nielsen VG: Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plas-min interactions. Blood Coagul Fibrinolysis 2007; 18: 647-56
100. Ruttmann TG, James MF, Finlayson J: Effects on coagulation of intravenous crystalloid or colloid in patients undergoing peripheral vascular surgery. Br J Anaesth 2002; 89:226-30
101. Kretschmer V, Daraktchiev A, Karger R: Does haemodi-lution produce a hypercoagulable state? Thromb Hae-most 2004; 92:670-1
102. Aarts PA, van den Broek SA, Prins GW, Kuiken GD, Sixma JJ, Heethaar RM: Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis 1988; 8:819-24
103. Blajchman MA, Bordin JO, Bardossy L, Heddle NM: The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol 1994; 86:347-50
104. Slichter SJ: Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18:153-67
105. Joist JH, Bauman JE, Sutera SP: Platelet adhesion and aggregation in pulsatile shear flow: Effects of red blood cells. Thromb Res 1998; 92:S47-52
106. Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S: A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: Evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Vox Sang 2003; 85: 290-9
107. Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka KA: Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg 2004; 99:1440-4
108. Downes KA, Wilson E, Yomtovian R, Sarode R: Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001; 41:570
109. Gonzalez EA, Moore FA, Holcomb JB, Miller CC, Kozar RA, Todd SR, Cocanour CS, Balldin BC, McKinley BA: Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62:112-9
110. Shaz BH, Dente CJ, Harris RS, MacLeod JB, Hillyer CD: Transfusion management of trauma patients. Anesth Analg 2009; 108:1760-8
111. Shaz BH, Dente CJ, Nicholas J, MacLeod JB, Young AN, Easley K, Ling Q, Harris RS, Hillyer CD: Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010; 50:493-500
112. Maegele M, Lefering R, Paffrath T, Tjardes T, Simanski C, Bouillon B, Working Group on Polytrauma of the German Society of Trauma Surgery (DGU): Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: A retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie. Vox Sang 2008; 95:112-9
113. Scalea TM, Bochicchio KM, Lumpkins K, Hess JR, Dutton R, Pyle A, Bochicchio GV: Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg 2008; 248:578-84
114. Snyder CW, Weinberg JA, McGwin G Jr., Melton SM, George RL, Reiff DA, Cross JM, Hubbard-Brown J, Rue LW 3rd, Kerby JD: The relationship of blood product ratio to mortality: Survival benefit or survival bias? J Trauma 2009; 66:358-62
115. Riskin DJ, Tsai TC, Riskin L, Hernandez-Boussard T, Pur-till M, Maggio PM, Spain DA, Brundage SI: Massive transfusion protocols: The role of aggressive resuscitation versus product ratio in mortality reduction. J Am Coll Surg 2009; 209:198-205
116. Roback JD, Caldwell S, Carson J, Davenport R, Drew MJ, Eder A, Fung M, Hamilton M, Hess JR, Luban N, Perkins JG, Sachais BS, Shander A, Silverman T, Snyder E, Tormey C, Waters J, Djulbegovic B: Evidence-based practice guidelines for plasma transfusion. Transfusion 2010; 50: 1227-39
117. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW: Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemosta-sis in critically ill patients. Br J Haematol 2004; 125: 69-73
118. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF: Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials Br J Haematol 2004; 126:139-52
119. Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, Cuschieri J, Maier RV, Billiar TR, Peitzman AB, Inflammation and Host Response to Injury Investigators: Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67:221-7
120. Riedler GF, Haycox AR, Duggan AK, Dakin HA: Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85:88-95
121. Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM, Serious Hazards of Transfusion Steering Group: Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49:440-52
122. Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, Erwin PJ, Montori VM, Roback JD: The effect of plasma transfusion on morbidity and mortality: A systematic review and meta-analysis. Transfusion 2010; 50:1370-83
123. Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JI, Gracias VH: Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008; 36:1114-8
124. Spahn DR, Rossaint R: Coagulopathy and blood component transfusion in trauma. Br J Anaesth 2005; 95:130-9
125. Solomon C, Pichlmaier U, Schoechl H, Hagl C, Raymon-dos K, Scheinichen D, Koppert W, Rahe-Meyer N: Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555-62
126. Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, Hess JR, Dubick MA, Simon CD, Beekley AC, Wolf SE, Wade CE, Holcomb JB: The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64:S79-85
127. Haas T, Fries D, Velik-Salchner C, Oswald E, Innerhofer P: Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106:725-31
128. Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn DR: In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM(R)). Thromb Haemost 2010; 104:385-91
129. Levy JH, Tanaka KA, Dietrich W: Perioperative hemo-static management of patients treated with vitamin K antagonists. ANESTHESIOLOGY 2008; 109:918-26
130. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Oster-mann H, Beriplex P/N Anticoagulation Reversal Study Group: Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. J Thromb Haemost 2008; 6:622-31
131. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE: Prothrombin complex concentrate (Oc-taplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121:9-16
132. Dickneite G, Doerr B, Kaspereit F: Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg 2008; 106:1070-7
133. Bruce D, Nokes TJ: Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: Experience in a large tertiary hospital. Crit Care 2008; 12:R105
134. Fraser TA, Corke CF, Mohajeri M, Stevenson L, Campbell PJ: A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Crit Care Resusc 2006; 8:141-5
135. Stuklis RG, O'Shaughnessy DF, Ohri SK: Novel approach to bleeding in patients undergoing cardiac surgery with liver dysfunction. Eur J Cardiothorac Surg 2001; 19:219-20
136. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, Locker GJ, Laczika K, Knapp S, Watzke H: Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999; 25:1105-10
137. Dusel CH, Grundmann C, Eich S, Seitz R, Konig H: Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004; 15:405-11
138. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y, NovoSeven Trauma Study Group: Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8-15
139. Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA, Australian and New Zealand Haemostasis Registry: Recombinant activated factor VII in obstetric hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009; 109:1908-15
140. Lewis NR, Brunker P, Lemire SJ, Kaufman RM: Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 2009; 49:689-95
141. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8
142. Kluger Y, Riou B, Rossaint R, Rizoli SB, Boffard KD, Choong PI, Warren B, Tillinger M: Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: Post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. Crit Care 2007; 11:R85
143. Sihler KC, Napolitano LM: Massive transfusion: New insights. Chest 2009; 136:1654-67
144. Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri J, Rosengart MR, Maier RV, Billiar TR, Peitzman AB, Moore EE, Inflammation the Host Response to Injury Investigators: An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65:986-93
145. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, Murkin J, Nadel A: Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-8
146. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B: Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102:4594-9
147. Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J: Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314:1402-6
148. Mannucci PM, Levi M: Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301-11
149. Carless PA, Henry DA, Moxey AJ, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D: Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004: CD001884
150. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D: Anti-fibrinolytict use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007:CD001886
151. CRASH-2 trial collaborators, Shakur H, Roberts R, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaish-vili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010; 376:23-32
152. Key NS, Negrier C: Coagulation factor concentrates: Past, present, and future. Lancet 2007; 370:439-48